|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang X, Shi S, Zhang B, Ni Q, Yu X and Xu
J: Circulating biomarkers for early diagnosis of pancreatic cancer:
Facts and hopes. Am J Cancer Res. 8:332–353. 2018.PubMed/NCBI
|
|
5
|
Venkitaraman AR: Cancer susceptibility and
the functions of BRCA1 and BRCA2. Cell. 108:171–182. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang L, Wu C, Yu D, Wang C, Che X, Miao
X, Zhai K, Chang J, Jiang G, Yang X, et al: Identification of
common variants in BRCA2 and MAP2K4 for susceptibility to sporadic
pancreatic cancer. Carcinogenesis. 34:1001–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sikdar N, Saha G, Dutta A, Ghosh S,
Shrikhande SV and Banerjee S: Genetic alterations of periampullary
and pancreatic ductal adenocarcinoma: An overview. Curr Genomics.
19:444–463. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B
and Yu X: PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Curr Biol. 19:524–529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reid S, Schindler D, Hanenberg H, Barker
K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, et al:
Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and
predispose to childhood cancer. Nat Genet. 39:162–164. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xia B, Dorsman JC, Ameziane N, de Vries Y,
Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, et al:
Fanconi anemia is associated with a defect in the BRCA2 partner
PALB2. Nat Genet. 39:159–161. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen P, Liang J, Wang Z, Zhou X, Chen L,
Li M, Xie D, Hu Z, Shen H and Wang H: Association of common PALB2
polymorphisms with breast cancer risk: A case-control study. Clin
Cancer Res. 14:5931–5937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Southey MC, Teo ZL and Winship I: PALB2
and breast cancer: Ready for clinical translation! Appl Clin Genet.
6:43–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borecka M, Zemankova P, Vocka M, Soucek P,
Soukupova J, Kleiblova P, Sevcik J, Kleibl Z and Janatova M:
Mutation analysis of the PALB2 gene in unselected pancreatic cancer
patients in the Czech Republic. Cancer Genet. 209:199–204. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blanco A, de la Hoya M, Osorio A, Diez O,
Miramar MD, Infante M, Martinez-Bouzas C, Torres A, Lasa A, Llort
G, et al: Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish
hereditary breast/ovarian cancer families with pancreatic cancer
cases. PLoS One. 8:e675382013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harinck F, Kluijt I, van Mil SE, Waisfisz
Q, van Os TA, Aalfs CM, Wagner A, Olderode-Berends M, Sijmons RH,
Kuipers EJ, et al: Routine testing for PALB2 mutations in familial
pancreatic cancer families and breast cancer families with
pancreatic cancer is not indicated. Eur J Hum Genet. 20:577–579.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hofstatter EW, Domchek SM, Miron A, Garber
J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL and
Tung N: PALB2 mutations in familial breast and pancreatic cancer.
Fam Cancer. 10:225–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takeuchi S, Doi M, Ikari N, Yamamoto M and
Furukawa T: Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50
cancer-associated genes in pancreatic ductal adenocarcinoma. Sci
Rep. 8:81052018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Golan T, Kanji ZS, Epelbaum R, Devaud N,
Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B,
Gershoni-Baruch R, et al: Overall survival and clinical
characteristics of pancreatic cancer in BRCA mutation carriers. Br
J Cancer. 111:1132–1138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wattenberg MM, Asch D, Yu S, O'Dwyer PJ,
Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES and
Reiss KA: Platinum response characteristics of patients with
pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or
PALB2 mutation. Br J Cancer. 122:333–339. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dell'Aquila E, Fulgenzi CAM, Minelli A,
Citarella F, Stellato M, Pantano F, Russano M, Cursano MC,
Napolitano A, Zeppola T, et al: Prognostic and predictive factors
in pancreatic cancer. Oncotarget. 11:924–941. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer-Verlag; New York, NY: 2009
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ducy M, Sesma-Sanz L, Guitton-Sert L,
Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron MC,
Côté J, et al: The tumor suppressor PALB2: Inside out. Trends
Biochem Sci. 44:226–240. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sy SM, Huen MS and Chen J: PALB2 is an
integral component of the BRCA complex required for homologous
recombination repair. Proc Natl Acad Sci USA. 106:7155–7160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang G, Mercado-Uribe I, Multani AS, Sen
S, Shih Ie M, Wong KK, Gershenson DM and Liu J: RAS promotes
tumorigenesis through genomic instability induced by imbalanced
expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int
J Cancer. 133:275–285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Egawa C, Miyoshi Y, Taguchi T, Tamaki Y
and Noguchi S: High BRCA2 mRNA expression predicts poor prognosis
in breast cancer patients. Int J Cancer. 98:879–882. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Li M, Chen P and Ba Q: High
expression of PALB2 predicts poor prognosis in patients with
advanced breast cancer. FEBS Open Bio. 8:56–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Poumpouridou N, Acha-Sagredo A, Goutas N,
Vlachodimitropoulos D, Chatziioannidou I, Lianidou E, Liloglou T
and Kroupis C: Development and validation of molecular
methodologies to assess PALB2 expression in sporadic breast cancer.
Clin Biochem. 49:253–259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bleuyard JY, Butler RM and Esashi F:
Perturbation of PALB2 function by the T413S mutation found in small
cell lung cancer. Wellcome Open Res. 2:1102017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakagomi H, Sakamoto I, Hirotsu Y, Amemiya
K, Mochiduki H and Omata M: Analysis of PALB2 mutations in 155
Japanese patients with breast and/or ovarian cancer. Int J Clin
Oncol. 21:270–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rahman N, Seal S, Thompson D, Kelly P,
Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, et
al: PALB2, which encodes a BRCA2-interacting protein, is a breast
cancer susceptibility gene. Nat Genet. 39:165–167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Casadei S, Norquist BM, Walsh T, Stray S,
Mandell JB, Lee MK, Stamatoyannopoulos JA and King MC: Contribution
of inherited mutations in the BRCA2-interacting protein PALB2 to
familial breast cancer. Cancer Res. 71:2222–2229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu Y, Zhai K, Ke J, Li J, Gong Y, Yang Y,
Tian J, Zhang Y, Zou D, Peng X, et al: BRCA1 missense polymorphisms
are associated with poor prognosis of pancreatic cancer patients in
a Chinese population. Oncotarget. 8:36033–36039. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jones S, Hruban RH, Kamiyama M, Borges M,
Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, et
al: Exomic sequencing identifies PALB2 as a pancreatic cancer
susceptibility gene. Science. 324:2172009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Slater EP, Langer P, Niemczyk E, Strauch
K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W and Bartsch DK:
PALB2 mutations in European familial pancreatic cancer families.
Clin Genet. 78:490–494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Giovannetti E, van der Borden CL, Frampton
AE, Ali A, Firuzi O and Peters GJ: Never let it go: Stopping key
mechanisms underlying metastasis to fight pancreatic cancer. Semin
Cancer Biol. 44:43–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Garces-Descovich A, Beker K,
Jaramillo-Cardoso A, James Moser A and Mortele KJ: Applicability of
current NCCN Guidelines for pancreatic adenocarcinoma
resectability: Analysis and pitfalls. Abdom Radiol (NY).
43:314–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lefebvre C, Bachelot T, Filleron T,
Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M,
Lacroix-Triki M, et al: Mutational profile of metastatic breast
cancers: A retrospective analysis. PLoS Med. 13:e10022012016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pritchard CC, Mateo J, Walsh MF, De Sarkar
N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R,
et al: Inherited DNA-Repair gene mutations in men with metastatic
prostate cancer. New Engl J Med. 375:443–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
